Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment. - Wikidata - wikimedia - TriplyDB

Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment.

Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment.

http://www.wikidata.org/entity/Q37543832

about

Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment.

http://www.wikidata.org/entity/Q37543832

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evaluation of Left Ventricular ...... ng-Term Trastuzumab Treatment.

@en

Evaluation of Left Ventricular ...... ng-Term Trastuzumab Treatment.

@nl

type

label

Evaluation of Left Ventricular ...... ng-Term Trastuzumab Treatment.

@en

Evaluation of Left Ventricular ...... ng-Term Trastuzumab Treatment.

@nl

prefLabel

Evaluation of Left Ventricular ...... ng-Term Trastuzumab Treatment.

@en

Evaluation of Left Ventricular ...... ng-Term Trastuzumab Treatment.

@nl

P1433

Q37543832-A25A3B56-FB1B-4696-87C3-0E81A2AFBD37

P1476

Q37543832-F593EE7C-968F-470F-977D-78EE80E89C49

P2093

Q37543832-06AA9DA8-9FD6-4A46-91A8-5E41A30B2192

Q37543832-49C0C159-520E-4311-9EDF-A5C6D9A5ED7B

Q37543832-89002C76-9C81-4F03-BB59-ED39DF9053DE

Q37543832-EB790C00-A78E-48D6-AA70-5C49C034CE88

P2860

Q37543832-0743B1A4-A526-4B91-8B70-0199BE916209

Q37543832-1FF727FD-DB4D-4569-AEA9-06F18922573F

Q37543832-2928A912-6CE7-47B9-9DDE-453D531DFAEB

Q37543832-2EAE1236-740E-4A17-BE18-9B05C5230C68

Q37543832-3098A13F-3E6F-47FE-9EF7-BEC2C064C8D0

Q37543832-32E900DC-FC0E-42A6-8E36-B370CC789E94

Q37543832-420F6A3B-D2F4-4FEA-AD02-4E6039189134

Q37543832-44D81575-2A68-4052-82AD-8DEAB9A76263

Q37543832-4E1614F0-C436-4BA0-9039-BA8499004CAF

Q37543832-52B5D61F-1130-40F7-BE39-E3FB4388D074

P304

Q37543832-0704B78A-3130-4C4F-9B5E-2FD9E059655A

P31

Q37543832-5F8110CB-578A-4BC4-952E-D2BF5E285947

P356

Q37543832-15E35BFA-5073-4390-B626-1D642ACD6208

P478

Q37543832-35C500E9-0063-4D18-8DD5-9B94387507C8

P577

Q37543832-2E7425AF-5748-4453-B32D-3BEEF35FB8D1

P698

Q37543832-84202CC3-EC2A-4189-A579-8F0FBADE90D2

P932

Q37543832-32F98983-6BB3-447E-889B-AF33FF613786

P356

P1433

Medical Science Monitor

P1476

Evaluation of Left Ventricular ...... ong-Term Trastuzumab Treatment

@en

P2093

Qiwen Zhang

http://www.w3.org/2001/XMLSchema#string

Tao Li

http://www.w3.org/2001/XMLSchema#string

Yong Sun

http://www.w3.org/2001/XMLSchema#string

Yuanpeng Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.

Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study.

Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.

Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.

Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).

A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer.

P304

5035-5040

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12659/MSM.898807

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28000658

http://www.w3.org/2001/XMLSchema#string

P932

5198746

http://www.w3.org/2001/XMLSchema#string